Cargando…

Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry

A robust top down proteomics method is presented for profiling alpha-synuclein species from autopsied human frontal cortex brain tissue from Parkinson's cases and controls. The method was used to test the hypothesis that pathology associated brain tissue will have a different profile of post-tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kellie, John F., Higgs, Richard E., Ryder, John W., Major, Anthony, Beach, Thomas G., Adler, Charles H., Merchant, Kalpana, Knierman, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107347/
https://www.ncbi.nlm.nih.gov/pubmed/25052239
http://dx.doi.org/10.1038/srep05797
_version_ 1782327588295802880
author Kellie, John F.
Higgs, Richard E.
Ryder, John W.
Major, Anthony
Beach, Thomas G.
Adler, Charles H.
Merchant, Kalpana
Knierman, Michael D.
author_facet Kellie, John F.
Higgs, Richard E.
Ryder, John W.
Major, Anthony
Beach, Thomas G.
Adler, Charles H.
Merchant, Kalpana
Knierman, Michael D.
author_sort Kellie, John F.
collection PubMed
description A robust top down proteomics method is presented for profiling alpha-synuclein species from autopsied human frontal cortex brain tissue from Parkinson's cases and controls. The method was used to test the hypothesis that pathology associated brain tissue will have a different profile of post-translationally modified alpha-synuclein than the control samples. Validation of the sample processing steps, mass spectrometry based measurements, and data processing steps were performed. The intact protein quantitation method features extraction and integration of m/z data from each charge state of a detected alpha-synuclein species and fitting of the data to a simple linear model which accounts for concentration and charge state variability. The quantitation method was validated with serial dilutions of intact protein standards. Using the method on the human brain samples, several previously unreported modifications in alpha-synuclein were identified. Low levels of phosphorylated alpha synuclein were detected in brain tissue fractions enriched for Lewy body pathology and were marginally significant between PD cases and controls (p = 0.03).
format Online
Article
Text
id pubmed-4107347
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-41073472014-08-20 Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry Kellie, John F. Higgs, Richard E. Ryder, John W. Major, Anthony Beach, Thomas G. Adler, Charles H. Merchant, Kalpana Knierman, Michael D. Sci Rep Article A robust top down proteomics method is presented for profiling alpha-synuclein species from autopsied human frontal cortex brain tissue from Parkinson's cases and controls. The method was used to test the hypothesis that pathology associated brain tissue will have a different profile of post-translationally modified alpha-synuclein than the control samples. Validation of the sample processing steps, mass spectrometry based measurements, and data processing steps were performed. The intact protein quantitation method features extraction and integration of m/z data from each charge state of a detected alpha-synuclein species and fitting of the data to a simple linear model which accounts for concentration and charge state variability. The quantitation method was validated with serial dilutions of intact protein standards. Using the method on the human brain samples, several previously unreported modifications in alpha-synuclein were identified. Low levels of phosphorylated alpha synuclein were detected in brain tissue fractions enriched for Lewy body pathology and were marginally significant between PD cases and controls (p = 0.03). Nature Publishing Group 2014-07-23 /pmc/articles/PMC4107347/ /pubmed/25052239 http://dx.doi.org/10.1038/srep05797 Text en Copyright © 2014, Macmillan Publishers Limited. All rights reserved http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Article
Kellie, John F.
Higgs, Richard E.
Ryder, John W.
Major, Anthony
Beach, Thomas G.
Adler, Charles H.
Merchant, Kalpana
Knierman, Michael D.
Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
title Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
title_full Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
title_fullStr Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
title_full_unstemmed Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
title_short Quantitative Measurement of Intact Alpha-Synuclein Proteoforms from Post-Mortem Control and Parkinson's Disease Brain Tissue by Intact Protein Mass Spectrometry
title_sort quantitative measurement of intact alpha-synuclein proteoforms from post-mortem control and parkinson's disease brain tissue by intact protein mass spectrometry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107347/
https://www.ncbi.nlm.nih.gov/pubmed/25052239
http://dx.doi.org/10.1038/srep05797
work_keys_str_mv AT kelliejohnf quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT higgsricharde quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT ryderjohnw quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT majoranthony quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT beachthomasg quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT adlercharlesh quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT merchantkalpana quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry
AT kniermanmichaeld quantitativemeasurementofintactalphasynucleinproteoformsfrompostmortemcontrolandparkinsonsdiseasebraintissuebyintactproteinmassspectrometry